Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.

被引：0
|
作者：
Si, Lu
Zou, Zhengyun
Zhang, Weizhen
Fang, Meiyu
Zhang, Xiaoshi
Luo, Zhiguo
Chen, Jing
Huang, Gang
Zhang, Peng
Cheng, Ying
Liu, Jiwei
Liu, Jiyan
Zhang, Junping
Wu, Di
Chen, Yu
Ma, Xiaobiao
Wei, Xiaoting
Sun, Peng
Jia, Zhongwei
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Renal Canc & Melanoma, Beijing, Peoples R China
[2] Nanjing Univ, Comprehens Canc Ctr word B7, Nanjing Drum Tower Hosp, Med Sch,Affiliated Hosp, Nanjing, Peoples R China
[3] Third Peoples Hosp Zhengzhou, Dept Internal Med Melanoma & Sarcoma, Zhengzhou, Peoples R China
[4] Univ Chinese Acad Sci, Dept Rare Canc & Head & Neck Med Oncol, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[5] Sun Yat Sen Univ, State Key Lab Oncol Southern China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China
[6] Fudan Univ, Shanghai Canc Ctr, Dept Gastrointestinal Med Oncol, Shanghai, Peoples R China
[7] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China
[8] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Ctr Canc, Wuhan, Peoples R China
[9] Cent South Univ, Dept Orthoped & Soft Tissue, Hunan Canc Hosp, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Peoples R China
[10] Zhengzhou Univ, Dept Bone & Soft Tissue Canc, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China
[11] Jilin Canc Hosp, Dept Oncol, Changchun, Peoples R China
[12] Dalian Med Univ, Dept Med Oncol, Affiliated Hosp 1, Dalian, Peoples R China
[13] Sichuan Univ, West China Hosp, Dept Biotherapy, Ctr Canc, Chengdu, Peoples R China
[14] Shanxi Bethune Hosp, Dept Thorac Oncol, Taiyuan, Peoples R China
[15] First Hosp Jilin Univ, Ctr Canc, Changchun, Peoples R China
[16] Fujian Med Univ, Fujian Canc Hosp, Dept Med Oncol, Clin Oncol Sch, Fuzhou, Peoples R China
[17] Kunming Med Univ, Dept Canc BiotherapyCtr, Yunnan Canc Hosp, Affiliated Hosp 3, Kunming, Peoples R China
[18] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Renal Canc & Melanoma, Beijing, Peoples R China
[19] Shanghai Kechow Pharma Inc, Dept Clin Res & Dev, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9510
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Overall survival and efficacy subgroup analysis of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study
    Wei, Xiaoting
    Zou, Zhengyun
    Zhang, Weizhen
    Fang, Meiyu
    Zhang, Xiaoshi
    Luo, Zhiguo
    Chen, Jing
    Huang, Gang
    Zhang, Peng
    Cheng, Ying
    Liu, Jiwei
    Liu, Jiyan
    Zhang, Junping
    Wu, Di
    Chen, Yu
    Ma, Xiaobiao
    Tian, Hongqi
    Jia, Zhongwei
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
    Wei, Xiaoting
    Zou, Zhengyun
    Zhang, Weizhen
    Fang, Meiyu
    Zhang, Xiaoshi
    Luo, Zhiguo
    Chen, Jing
    Huang, Gang
    Zhang, Peng
    Cheng, Ying
    Liu, Jiwei
    Liu, Jiyan
    Zhang, Junping
    Wu, Di
    Chen, Yu
    Ma, Xiaobiao
    Pan, Hongming
    Jiang, Renbing
    Liu, Xinlan
    Ren, Xiubao
    Tian, Hongqi
    Jia, Zhongwei
    Guo, Jun
    Si, Lu
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [3] Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: A multicenter, open-label, single-arm phase 2 study.
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Bai, Xue
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Xu, Jiahui
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] A phase III, open-label, multicenter, randomized controlled trial of tunlametinib versus investigator-selected chemotherapy in patients with advanced NRAS-mutant melanoma who had previously received immunotherapy
    Wei, Xiaoting
    Zhang, Weizhen
    Fang, Meiyu
    Zou, Zhengyun
    Chen, Jing
    Luo, Zhiguo
    Tian, Hongqi
    Jia, Zhongwei
    Guo, Jun
    Si, Lu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Suwanvecho, Suthida
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
  • [6] Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
    Namikawa, Kenjiro
    Kiyohara, Yoshio
    Takenouchi, Tatsuya
    Uhara, Hisashi
    Uchi, Hiroshi
    Yoshikawa, Shusuke
    Takatsuka, Sumiko
    Koga, Hiroshi
    Wada, Naoko
    Minami, Hironobu
    Hatsumichi, Masahiro
    Asada, Suguru
    Namba, Yoshinobu
    Yamazaki, Naoya
    EUROPEAN JOURNAL OF CANCER, 2018, 105 : 114 - 126
  • [7] Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study
    Yap, Timothy A.
    Nakagawa, Kazuhiko
    Fujimoto, Nobukazu
    Kuribayashi, Kozo
    Guren, Tormod Kyrre
    Calabro, Luana
    Shapira-Frommer, Ronnie
    Gao, Bo
    Kao, Steven
    Matos, Ignacio
    Planchard, David
    Chatterjee, Arkendu
    Jin, Fan
    Norwood, Kevin
    Kindler, Hedy L.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (06): : 613 - 621
  • [8] Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
    de Braud, Filippo
    Dooms, Christophe
    Heist, Rebecca S.
    Lebbe, Celeste
    Wermke, Martin
    Gazzah, Anas
    Schadendorf, Dirk
    Rutkowski, Piotr
    Wolf, Juergen
    Ascierto, Paolo A.
    Gil-Bazo, Ignacio
    Kato, Shumei
    Wolodarski, Maria
    McKean, Meredith
    Couselo, Eva Munoz
    Sebastian, Martin
    Santoro, Armando
    Cooke, Vesselina
    Manganelli, Luca
    Wan, Kitty
    Gaur, Anil
    Kim, Jaeyeon
    Caponigro, Giordano
    Couillebault, Xuan-Mai
    Evans, Helen
    Campbell, Catarina D.
    Basu, Sumit
    Moschetta, Michele
    Daud, Adil
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2651 - +
  • [9] Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study
    Shi, Yuankai
    Han, Xiaohong
    Zhao, Qian
    Zheng, Yulong
    Chen, Jianhua
    Yu, Xinmin
    Fang, Jian
    Liu, Yutao
    Huang, Dingzhi
    Liu, Tianshu
    Shen, Hong
    Luo, Suxia
    Yu, Hongsheng
    Cao, Yu
    Zhang, Xi
    Hu, Pei
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2024, 13 (01)
  • [10] A Multicenter, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of Hetrombopag in Patients with Severe Aplastic Anemia (SAA)
    Zhang, Fengkui
    Peng, Guangxin
    He, Guangsheng
    Chang, Hong
    Gao, Sujun
    Liu, Xinjian
    Chen, Tong
    Li, Pei
    Han, Bing
    Miao, Miao
    Ge, Zheng
    Ge, Xiaoyan
    Li, Fei
    Li, Yingmei
    Wang, Shunqing
    Wang, Yi
    Shen, Yaqi
    Tai, Yanfei
    Zhang, Tao
    Zhu, Bo
    Zou, Jianjun
    BLOOD, 2020, 136
12345